Mass Tort brief
Bayer's Roundup Preemption Test and the First Major Device Trials
Federal courts test whether sweeping preemption rulings force toxic tort settlements as juries hand down landmark verdicts in medical device litigation.
Mass Tort
Judge Chhabria is scrutinizing Bayer's $7.25B Roundup settlement — deciding whether a conservative Supreme Court ruling traps cancer victims in 21-year installment terms.
BackgroundBayer acquired agrochemical giant Monsanto in 2018, inheriting tens of thousands of product liability lawsuits alleging glyphosate weedkiller causes non-Hodgkin lymphoma. The Supreme Court's ruling in Monsanto v. Durnell held that EPA-approved warning labels legally preempt state-law failure-to-warn claims.
- The proposed nationwide agreement pays cancer claimants between $10,000 and $165,000 across a 21-year structured timeline, drawing intense backlash from victims' families.
- Objecting plaintiff attorneys argued that the settlement undervalues catastrophic injuries and creates coercive opt-out barriers designed solely to insulate Bayer from future jury trials.
- Judge Chhabria instructed the parties to submit revised settlement orders while probing whether federal multidistrict claimants can be lawfully bound by a state court class deal.
Mass Tort
Daubert hearings closed in the Ozempic MDL — leaving Judge Marston to decide whether gastroparesis science reaches a jury or gets dismissed wholesale.
BackgroundMultidistrict litigation centralizes complex federal personal injury lawsuits before a single judge to coordinate discovery and conduct early bellwether test trials. Plaintiffs allege blockbuster diabetes and obesity drugs including Ozempic, Wegovy, and Mounjaro cause debilitating digestive paralysis and intestinal blockages without clear warnings.
- The Rule 702 Daubert hearings evaluated medical studies on general causation, examining whether GLP-1 receptor agonists directly trigger permanent stomach paralysis or simply slow digestion temporarily.
- Manufacturers Novo Nordisk and Eli Lilly contend that gastric slowing is an expected clinical effect rather than an actionable defect, arguing epidemiological proof of chronic injury is absent.
- A ruling certifying plaintiffs' scientific experts would prompt the court to schedule the first bellwether trials, placing immense settlement pressure on both pharmaceutical giants.
Mass Tort
A $40M verdict for a broken Bard port catheter that reached a patient's heart hands 3,700 plaintiffs steep leverage heading into subsequent bellwether trials.
BackgroundImplantable port catheters are surgically placed beneath the skin to deliver chemotherapy and vital medications directly into large veins. Thousands of patients allege that barium sulfate added for X-ray visibility degraded the polyurethane tubing, leading to dangerous fractures and vascular blood clots.
- Jurors found C.R. Bard and parent company Becton Dickinson guilty of design defect and negligent failure to warn doctors about catheter degradation and breakage risks.
- The plaintiff required emergency open-chest surgical extraction after fragmented tubing drifted into her bloodstream, causing life-threatening cardiac trauma and persistent psychological distress.
- The $40 million compensatory judgment resets settlement valuations dramatically higher as the federal court prepares a slate of subsequent bellwether trials for 2027.
Mass Tort
Pfizer is finalizing a master settlement for 6,400 Depo-Provera brain tumor claims — forcing plaintiffs to register by November 30 or face steep evidentiary screens.
BackgroundDepo-Provera is an injectable progestin contraceptive administered to millions of women every three months since its FDA clearance in 1992. Lawsuits allege that prolonged use of high-dose medroxyprogesterone acetate dramatically raises the danger of developing meningiomas, benign cranial tumors that often necessitate invasive brain surgery.
- The federal multidistrict docket has surged to 6,411 lawsuits representing 6,775 individual plaintiffs claiming Pfizer failed to adequately warn patients and prescribers about intracranial tumor risks.
- The master settlement framework is expected to resolve roughly 80% of active federal filings, pausing trial schedules while claimants submit certified medical documentation to a neutral administrator.
- Claimants who bypass the November 30 deadline must satisfy stringent threshold injury screening protocols to continue pursuing individual trial dates in federal court.
Mass Tort
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
